EN6
CAS No. 1808714-73-9
EN6( —— )
Catalog No. M23822 CAS No. 1808714-73-9
EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 72 | In Stock |
|
| 10MG | 125 | In Stock |
|
| 25MG | 194 | In Stock |
|
| 50MG | 250 | In Stock |
|
| 100MG | 380 | In Stock |
|
| 500MG | 861 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEN6
-
NoteResearch use only, not for human use.
-
Brief DescriptionEN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling.
-
DescriptionEN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy.?EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner.?EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).?
-
In VitroWestern Blot Analysis Cell Line:HEK293A cells Concentration:50 μM Incubation Time:1, 4, 8 h Result:Time- and dose-dependently triggered formation of LC3 puncta and increased the levels of LC3BII.Western Blot Analysis Cell Line:HEK293A cells Concentration:25 μM Incubation Time:1 h Result:Led to complete inactivation of mTORC1 signaling, as shown by reduced levels of phosphorylated canonical substrates, S6 kinase 1 (S6K1), 4EBP1, and ULK1. Immunofluorescence Cell Line:HEK293A cells Concentration:50 μM Incubation Time:4 h Result:Led to significantly increased acidification of the lysosome in HEK293A cells, and this heightened acidification was blocked by BafA1.Immunofluorescence Cell Line:IPTG-inducible GFP-TDP43 U2OS osteosarcoma cell line model Concentration:25 μM Incubation Time:7 h Result:Reduced IPTG-induced TDP43 aggregates by 75 %.
-
In VivoAnimal Model:Six-week-old male C57BL/6 mice.Dosage:50 mg/kg Administration:Intraperitoneal injection; single Result:Significantly inhibited mTORC1 signaling in both skeletal muscle and heart, as demonstrated by reduced phosphorylation of S6, 4EBP1 and ULK1.Strongly activated autophagy as shown by heightened LC3BII levels and reduced p62 levels.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1808714-73-9
-
Formula Weight368.34
-
Molecular FormulaC19H14F2N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 4.63 mg/mL (12.57 mM; Need ultrasonic); Ethanol: 1.10 mg/mL (2.99 mM; ultrasonic and warming and heat to 60°C)
-
SMILESC=CC(Nc(cc(cc1)NC(c2cn(-c(cccc3)c3F)nc2)=O)c1F)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chung CY, et al. Covalent targeting of the vacuolar H+-ATPase activates autophagy via mTORC1 inhibition. Nat Chem Biol. 2019 Aug;15(8):776-785.
molnova catalog
related products
-
PACAP (1-38), human,...
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), and VIP release. PACAP 1-38 (10-8 M) inhibited gastrin secretion and stimulated somatostatin secretion and motility dose-dependently.
-
IPN60090
IPN60090 is a novel, potent, orally bioavailable, renal-type glutaminase (GLS1)-specific inhibitor with an IC50 value of 31 nM for GLS1.
-
2',4,4',6'-Tetrameth...
2',4,4',6'-Tetramethoxychalcone is a natural product.
Cart
sales@molnova.com